1. Home
  2. CSWC vs AGIO Comparison

CSWC vs AGIO Comparison

Compare CSWC & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capital Southwest Corporation

CSWC

Capital Southwest Corporation

HOLD

Current Price

$21.46

Market Cap

1.3B

ML Signal

HOLD

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$29.43

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CSWC
AGIO
Founded
1961
2007
Country
United States
United States
Employees
30
N/A
Industry
Textiles
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.6B
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
CSWC
AGIO
Price
$21.46
$29.43
Analyst Decision
Buy
Buy
Analyst Count
5
8
Target Price
$23.50
$37.63
AVG Volume (30 Days)
567.6K
646.9K
Earning Date
05-13-2026
04-30-2026
Dividend Yield
11.74%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$43,011,000.00
Revenue This Year
$17.45
$71.05
Revenue Next Year
$10.26
$163.65
P/E Ratio
$12.65
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.47
$22.24
52 Week High
$23.84
$46.00

Technical Indicators

Market Signals
Indicator
CSWC
AGIO
Relative Strength Index (RSI) 38.64 56.39
Support Level $21.30 $26.48
Resistance Level $23.19 $29.49
Average True Range (ATR) 0.44 1.02
MACD 0.00 0.15
Stochastic Oscillator 19.74 61.24

Price Performance

Historical Comparison
CSWC
AGIO

About CSWC Capital Southwest Corporation

Capital Southwest Corp is a U.S.-based investment company that specializes in providing customized financing to middle market companies across various industries. The company's investment objective is to produce attractive risk-adjusted returns by generating current income from debt investments and capital appreciation from equity and equity related investments. It focuses on providing flexible financing solutions through partnerships with business owners, management teams, and financial sponsors. The company's portfolio may include senior debt, second lien, and subordinated debt, preferred stocks, common stocks, and warrants. The primary source company's revenue comprises interest income and dividend income from investments made as well as management fees.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Share on Social Networks: